Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
If this drug does show promise even if marginal...Amgen or like company with buy so fast your head will spin....Ya Dig! I've spent 30 years in the pharmaceutical business.
J.C. Penney's Problems Can Be Fixed [View article]
Within 12 months....but just a wild guess. I buy almost ALL my clothes online. Tip: If you want one great pair of dress slacks for men or women get Zanella. They best! Ya Dig!
J.C. Penney's Problems Can Be Fixed [View article]
Hedge funds not all make good decisions. These people probably don't even shop at JCP. Hey if they can make 10% in the short term then sell, they will make some $$$....this company is toast. Go look at who is working there...the bottom of the barrel...Ya Dig!
J.C. Penney's Problems Can Be Fixed [View article]
You are 100% correct. Look at the clothes people wear...they look like slobs...esp over the last 15 years..no pride of ownership...dumbing down of America...Ya Dig!
J.C. Penney's Problems Can Be Fixed [View article]
No..JCP is the odd man out. Nothing but hard-ache all over. The people working there want out...not a friendly place, plus the young kids who work now do not give a rats you know what about customer serivce. Many companies could learn from "Publix" and the founder Mr. George Jenkins on how to take care of the customer. Ya Dig!
Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a third indication as the FDA approves the drug for the treatment of opioid-induced constipation. Cantor Fitzgerald previously said AMITIZA could ultimately prove to be a major catalyst for shares of SCMP which are up a quick 13.6% premarket. [View news story]
Looks like a winner. Takeda needs to go ahead and buy at this low price...ya Dig!
Why I Believe Oncothyreon Is The Stock To Own Into 2013 [View article]
Question: Most cancer trails I read the difference between the two on survival rates is around 2-4 months. In this trial it's a "whopping" 17 months longer. This is one BIG number. If it is correct ALL cancer docs will use this product. Tell me I'm wrong or read the data wrong>>
An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court. [View news story]
The docs want the facts. Don't let the FDA bully all the companies just so they can get free money...in the way of fines.
yes and no....in retail only about 5% of the employees will make real money. That's how it's been forever in retail. Who really wants to work there? Not me...then they hire people many with chip on their shoulders....and it spreads. Catch 22!
Is Xoma Ready To Rise? [View article]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
http://bit.ly/YBUXpz
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
J.C. Penney's Problems Can Be Fixed [View article]
J.C. Penney's Problems Can Be Fixed [View article]
J.C. Penney's Problems Can Be Fixed [View article]
J.C. Penney's Problems Can Be Fixed [View article]
J.C. Penney's Problems Can Be Fixed [View article]
Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a third indication as the FDA approves the drug for the treatment of opioid-induced constipation. Cantor Fitzgerald previously said AMITIZA could ultimately prove to be a major catalyst for shares of SCMP which are up a quick 13.6% premarket. [View news story]
CVS Earnings Preview: The Upside Catalysts Are Fading [View article]
CVS Caremark Corporation To Hold Fourth Quarter 2012 Conference Call [View article]
Why I Believe Oncothyreon Is The Stock To Own Into 2013 [View article]
An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court. [View news story]
Is Wal-Mart's Evil Image Deserved? [View article]